Farther Finance Advisors LLC Increases Position in Regeneron Pharmaceuticals, Inc. $REGN

Farther Finance Advisors LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 134.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,479 shares of the biopharmaceutical company’s stock after purchasing an additional 848 shares during the period. Farther Finance Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $832,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $38,000. Berbice Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares during the period. Finally, Westside Investment Management Inc. increased its stake in Regeneron Pharmaceuticals by 62.0% during the 2nd quarter. Westside Investment Management Inc. now owns 81 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on REGN shares. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research report on Wednesday, October 29th. Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $798.00 price target on the stock. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Finally, BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $779.45.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6%

NASDAQ:REGN opened at $780.50 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $792.77. The stock has a market cap of $82.03 billion, a P/E ratio of 18.69, a P/E/G ratio of 2.26 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The stock has a 50-day simple moving average of $707.58 and a 200-day simple moving average of $612.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $12.46 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.